Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCEUJD)

• Drug Name: Clorgyline Drug Info
• Synonyms: Chlorgyline; Clorgilin; Clorgilina; Clorgiline; Clorgilinum; Clorgiline [INN]; M and B 9302; Clorgilina [INN-Spanish]; Clorgiline (INN); Clorgilinum [INN-Latin]; M & B 9302; N-methyl-n-propargyl-3-(2,4-dichlorophenoxy)propylamine; N-(3-(2,4-Dichlorophenoxy)propyl)-N-methyl-2-propynylamine; N-[3-(2,4-DICHLOROPHENOXY)PROPYL]-N-METHYL-N-PROP-2-YNYLAMINE; 2-Propyn-1-amine, N-(3-(2,4-dichlorophenoxy)propyl)-N-methyl-(9CI); 3-(2,4-dichlorophenoxy)-N-methyl-N-prop-2-ynylpropan-1-amine

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Approved	[1]
Skin imperfections	EK71	Patented	[2]

• Therapeutic Class: Antiparkinson Agents
• Cross-matching ID:
  PubChem CID: 4380
  ChEBI ID: CHEBI:3763
  CAS Number: CAS 17780-72-2
  TTD Drug ID: DMCEUJD

Molecule-Related Drug Atlas

Drug(s) Targeting Monoamine oxidase (MAO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Moclobemide	DMNZWL7	Depression	6A70-6A7Z	Approved	[2]
Phenelzine	DMHIDUE	Depression	6A70-6A7Z	Approved	[2]
Tranylcypromine	DMGB5RE	Major depressive disorder	6A70.3	Approved	[2]
Selegiline	DM6034S	Major depressive disorder	6A70.3	Approved	[2]
Methylene blue	DMJAPE7	Acquired methemoglobinemia	3A93	Approved	[6]
Pargyline	DMM0HR1	Hypertension	BA00-BA04	Approved	[2]
Ergoloid mesylate	DMORPBA	Alzheimer disease	8A20	Approved	[7]
Cyclopropylamine derivative 11	DMMJ0YN	N. A.	N. A.	Patented	[8]
PMID27019002-Compound-20a	DMRX748	N. A.	N. A.	Patented	[8]
Cyclopropylamine derivative 9	DMX7YAL	N. A.	N. A.	Patented	[8]

Drug(s) Targeting Monoamine oxidase type A (MAO-A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Moclobemide	DMNZWL7	Depression	6A70-6A7Z	Approved	[9]
Tranylcypromine	DMGB5RE	Major depressive disorder	6A70.3	Approved	[10]
Isocarboxazid	DMAF1NB	Depression	6A70-6A7Z	Approved	[11]
TRYPTAMINE	DMAFPHB	N. A.	N. A.	Phase 3	[12]
Psoralen	DMIZJ8M	N. A.	N. A.	Phase 3	[13]
CHF-3381	DMQ2O8V	Neuropathic pain	8E43.0	Phase 2	[14]
Ladostigil	DMJSY3Q	Alzheimer disease	8A20	Phase 2	[15]
CX157	DMS2WB5	Mood disorder	6A60-6E23	Phase 2	[16]
PIPERINE	DMYEAB1	Vitiligo	ED63.0	Phase 1/2	[17]
Desoxypeganine	DMTR7EH	Alcohol dependence	6C40.2	Phase 1	[18]

Drug(s) Affected By Amine oxidase A (MAOA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[19]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[21]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[22]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[23]
Selegiline	DM6034S	Major depressive disorder	6A70.3	Approved	[24]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[25]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
BENZYL BENZOATE	DMDPYI5	Infestations of lice and scabies	1G00.Z	Approved	[28]

Drug(s) Affected By Cytochrome P450 2B6 (CYP2B6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[29]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[30]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[31]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[32]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[33]
Clopidogrel	DMOL54H	Acute coronary syndrome	BA41	Approved	[34]
Artemisinin	DMOY7W3	Malaria	1F40-1F45	Approved	[35]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[36]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[37]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[38]

Drug(s) Affected By Transcription factor TFIIIB component B'' homolog (BDP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[40]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[41]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[43]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[44]
Geldanamycin	DMS7TC5	Kidney cancer	2C90.0	Discontinued in Phase 2	[45]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[46]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[47]

Drug(s) Affected By Structural maintenance of chromosomes flexible hinge domain-containing protein 1 (SMCHD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[48]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[49]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[50]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[52]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[53]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[54]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[43]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[48]

Drug(s) Affected By Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha (PIK3C2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[55]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[50]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[57]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[58]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[59]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[60]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[61]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[58]

Drug(s) Affected By Suppressor of cytokine signaling 2 (SOCS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[62]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[63]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[63]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[64]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[65]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[66]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[67]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[68]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[69]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]

Drug(s) Affected By Calmegin (CLGN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[70]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[71]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[70]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[64]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[72]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[67]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[68]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[47]

Drug(s) Affected By Centrosomal protein of 290 kDa (CEP290)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[48]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[74]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[75]
Bortezomib	DMNO38U	Leukemia		Approved	[57]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[52]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[53]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[48]

Drug(s) Affected By Regulator of G-protein signaling 5 (RGS5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[76]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[64]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[64]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[40]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[77]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[64]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[78]

Drug(s) Affected By DNA polymerase zeta catalytic subunit (REV3L)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[79]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[81]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[82]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[58]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[60]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[58]
Vinblastine	DM5TVS3	Advanced cancer	2A00-2F9Z	Approved	[83]

Drug(s) Affected By Nuclear receptor subfamily 1 group I member 2 (NR1I2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[84]
Vidarabine	DM0N85H	Hepatosplenic T-cell lymphoma		Approved	[84]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[85]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[86]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[87]
Etidronic acid	DM1XHYJ	Bone Paget disease		Approved	[84]
Tiaprofenic acid	DM23D7J	Osteoarthritis	FA00-FA05	Approved	[84]
Bromperidol	DM24XYQ	Schizophrenia	6A20	Approved	[84]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[88]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[89]

Drug(s) Affected By Carboxypeptidase D (CPD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[48]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[90]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[91]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[67]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[57]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[92]

Drug(s) Affected By PHD finger protein 14 (PHF14)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[93]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[75]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[60]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[94]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[95]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[96]

Drug(s) Affected By Fibrinogen silencer-binding protein (RAD54B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[97]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[71]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[49]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[68]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[64]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[75]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[98]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[82]

Drug(s) Affected By Kelch-like protein 2 (KLHL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[69]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[99]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[100]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[64]

Drug(s) Affected By Lecithin retinol acyltransferase (LRAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[71]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[63]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[101]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[102]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[43]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[103]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[44]

Drug(s) Affected By Hemoglobin subunit delta (HBD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[104]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[105]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[106]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[50]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[107]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[108]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[100]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[109]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[50]

Drug(s) Affected By Prostate-specific antigen (KLK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[110]
Levonorgestrel	DM1DP7T	Atypical endometrial hyperplasia		Approved	[111]
Selenium	DM25CGV	N. A.	N. A.	Approved	[112]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[113]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[114]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[115]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[116]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[117]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[118]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[66]

Drug(s) Affected By Beta-2 adrenergic receptor (ADRB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salmeterol	DMIEU69	Allergic asthma	CA23.0	Approved	[119]
Bambuterol	DMKLSHF	Asthma	CA23	Approved	[120]
Terbutaline	DMD4381	Asthma	CA23	Approved	[121]
Salbutamol	DMN9CWF	Acute asthma	CA23	Approved	[122]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[123]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[124]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[125]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[22]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[126]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[127]

Drug(s) Affected By Complement factor H (CFH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[48]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[21]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[93]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[128]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[129]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[130]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[131]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[132]

Drug(s) Affected By Androgen receptor (AR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[133]
Nilutamide	DMFN07X	Prostate cancer	2C82.0	Approved	[133]
Hydroxyflutamide	DMGIZF5	Prostate cancer	2C82.0	Approved	[133]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[134]
Bicalutamide	DMZMSPF	Prostate cancer	2C82.0	Approved	[135]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[136]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[137]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[138]
Selenium	DM25CGV	N. A.	N. A.	Approved	[112]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[139]

Drug(s) Affected By Rab proteins geranylgeranyltransferase component A 1 (CHM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[50]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[75]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[140]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[43]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[100]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[141]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[142]

Drug(s) Affected By Adenomatous polyposis coli protein (APC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[143]
Selenium	DM25CGV	N. A.	N. A.	Approved	[48]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[144]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[79]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[65]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[106]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[145]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[146]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[147]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[148]

Drug(s) Affected By Tumor necrosis factor receptor superfamily member 6 (FAS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[149]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[150]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[151]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[152]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[153]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[154]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[155]
Fructose	DM43AN2	Vomiting	MD90	Approved	[156]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[149]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[157]

Drug(s) Affected By AT-rich interactive domain-containing protein 4A (ARID4A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[46]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[74]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[146]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[148]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[158]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[159]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[96]

Drug(s) Affected By CAP-Gly domain-containing linker protein 1 (CLIP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[160]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[161]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[162]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[60]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[163]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[164]

Drug(s) Affected By Glycerol kinase (GK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[62]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[90]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[165]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[166]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[129]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[57]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[52]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[167]

Drug(s) Affected By Melanoma-associated antigen 3 (MAGEA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[168]
Azacitidine	DMTA5OE	Acute myelogenous leukaemia	2A41	Approved	[169]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[96]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[100]

Drug(s) Affected By Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial (ACADSB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[170]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[166]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Chenodiol	DMQ8JIK	Cholelithiasis	DC11	Approved	[171]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[172]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[102]

Drug(s) Affected By Transcriptional regulator ATRX (ATRX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[173]
Selenium	DM25CGV	N. A.	N. A.	Approved	[48]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[79]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[174]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[93]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[175]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[57]

Drug(s) Affected By Nuclear receptor-interacting protein 1 (NRIP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[110]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[105]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[64]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[67]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[68]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[176]
Teniposide	DMLW57T	Acute lymphoblastic leukaemia	2A85	Approved	[177]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[178]

Drug(s) Affected By Selenoprotein P (SELENOP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[161]
Selenium	DM25CGV	N. A.	N. A.	Approved	[48]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[179]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[64]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[49]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[165]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[180]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[67]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]

Drug(s) Affected By DNA ligase 4 (LIG4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[180]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[181]
Bortezomib	DMNO38U	Leukemia		Approved	[57]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[182]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[183]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[99]
Fenfluramine	DM0762O	Dravet syndrome	8A61.11	Phase 3	[184]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[100]

Drug(s) Affected By TATA element modulatory factor (TMF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[48]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[93]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[50]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[60]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[185]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[48]

Drug(s) Affected By Dystonin (DST)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[186]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[46]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[79]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[64]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[187]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[188]
Bortezomib	DMNO38U	Leukemia		Approved	[189]

Drug(s) Affected By Centromere protein C (CENPC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[49]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[68]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Bortezomib	DMNO38U	Leukemia		Approved	[57]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[41]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[96]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[44]

Drug(s) Affected By GA-binding protein alpha chain (GABPA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[190]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[158]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[46]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[142]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[64]
GW7604	DMCA4RM	Discovery agent	N.A.	Investigative	[190]
2-tert-butylbenzene-1,4-diol	DMNXI1E	Discovery agent	N.A.	Investigative	[191]

Drug(s) Affected By Lymphotoxin-beta (LTB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[192]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[193]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[194]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[68]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Sanguinarine	DMDINFS	Dental plaque	DA08.4	Approved	[193]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[195]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[196]
Chloroquine	DMSI5CB	Malaria	1F40-1F45	Approved	[197]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[198]

Drug(s) Affected By Voltage-dependent L-type calcium channel subunit beta-2 (CACNB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[64]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[49]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[146]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[199]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[200]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[102]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[100]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[44]

Drug(s) Affected By TBC1 domain family member 8B (TBC1D8B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[48]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[71]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[50]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[201]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[98]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[60]

Drug(s) Affected By Golgin subfamily A member 4 (GOLGA4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[173]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[93]
Tubocurarine	DMBZIVP	Anaesthesia	9A78.6	Approved	[183]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Mecamylamine	DMGQFYB	Essential hypertension	BA00	Approved	[183]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[75]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[202]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[183]

Drug(s) Affected By Protein NPAT (NPAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[57]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[158]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[203]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[96]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[142]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[204]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[205]

Drug(s) Affected By Golgin subfamily B member 1 (GOLGB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[180]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[201]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[147]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[140]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[206]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[99]
DNCB	DMDTVYC	Immune System disease	4A01-4B41	Phase 2	[207]

Drug(s) Affected By Arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 2 (ACAP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[147]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[158]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[99]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[208]
Geldanamycin	DMS7TC5	Kidney cancer	2C90.0	Discontinued in Phase 2	[45]

Drug(s) Affected By Pericentriolar material 1 protein (PCM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[209]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[173]
Selenium	DM25CGV	N. A.	N. A.	Approved	[48]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[187]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[47]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[50]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[188]

Drug(s) Affected By Thyroid receptor-interacting protein 11 (TRIP11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[161]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[60]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[183]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[46]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[142]

Drug(s) Affected By Histone-lysine N-methyltransferase EZH2 (EZH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[161]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[210]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[46]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[21]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[211]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[212]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[213]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[66]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[66]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]

Drug(s) Affected By Nuclear factor erythroid 2-related factor 2 (NFE2L2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[214]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[215]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[216]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[217]
Selenium	DM25CGV	N. A.	N. A.	Approved	[48]
TECFIDERA	DM2OVDT	Multiple sclerosis	8A40	Approved	[218]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[219]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[220]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Furazolidone	DM3P6V7	Diarrhea	ME05.1	Approved	[221]

Drug(s) Affected By Chromodomain-helicase-DNA-binding protein 9 (CHD9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[48]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[22]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[67]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[68]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[188]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[41]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[96]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[208]

Drug(s) Affected By Microtubule-associated protein 9 (MAP9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[69]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[43]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[106]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[206]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[103]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[44]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[46]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[186]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[64]

Drug(s) Affected By Cordon-bleu protein-like 1 (COBLL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[71]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[64]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[25]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[69]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[81]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]

Drug(s) Affected By N-acetyltransferase ESCO1 (ESCO1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[68]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[53]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[43]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[100]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[46]
Geldanamycin	DMS7TC5	Kidney cancer	2C90.0	Discontinued in Phase 2	[45]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[142]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[204]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[47]

Drug(s) Affected By Sterile alpha motif domain-containing protein 9 (SAMD9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[222]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[223]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[66]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[66]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[68]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[75]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[224]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[52]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[53]

Drug(s) Affected By Glycoprotein endo-alpha-1,2-mannosidase (MANEA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[161]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[199]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[26]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[225]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[226]

Drug(s) Affected By MAGUK p55 subfamily member 7 (MPP7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[161]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[170]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[68]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[188]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[52]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[40]

Drug(s) Affected By 5'-nucleotidase domain-containing protein 1 (NT5DC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[53]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
DNCB	DMDTVYC	Immune System disease	4A01-4B41	Phase 2	[207]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[227]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[44]

Drug(s) Affected By Centrosome-associated protein 350 (CEP350)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[48]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[124]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[66]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[66]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[198]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[40]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[43]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[48]

Drug(s) Affected By Cysteine-rich hydrophobic domain-containing protein 1 (CHIC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[44]
Glyphosate	DM0AFY7	Malaria	1F40-1F45	Investigative	[228]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[204]

Drug(s) Affected By Muscleblind-like protein 2 (MBNL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[71]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[187]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[68]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[93]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[229]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[230]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]

Drug(s) Affected By La-related protein 1B (LARP1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[65]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[67]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[50]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[81]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[161]

Drug(s) Affected By Centrosomal protein of 135 kDa (CEP135)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[79]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[74]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[47]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[50]
Tamibarotene	DM3G74J	T-cell leukaemia	2A90	Phase 3	[79]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[100]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[44]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[231]

Drug(s) Affected By Nipped-B-like protein (NIPBL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[48]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[46]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[71]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[53]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[43]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[99]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[178]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[48]
Afimoxifene	DMFORDT	Breast cancer	2C60-2C65	Phase 2	[232]

Drug(s) Affected By Rapamycin-insensitive companion of mTOR (RICTOR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[233]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[46]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[71]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[198]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[233]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[60]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[234]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[99]

Drug(s) Affected By Ankyrin repeat domain-containing protein 12 (ANKRD12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[25]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[235]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[68]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[50]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[236]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]

Drug(s) Affected By Syntaxin-binding protein 4 (STXBP4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[195]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[46]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[47]

Drug(s) Affected By Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 2 protein (PREX2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[124]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[195]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[199]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[100]

Drug(s) Affected By MOB kinase activator 1B (MOB1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[186]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[99]
DNCB	DMDTVYC	Immune System disease	4A01-4B41	Phase 2	[207]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[237]
crotylaldehyde	DMTWRQI	Discovery agent	N.A.	Investigative	[238]

Drug(s) Affected By Protein MON2 homolog (MON2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[48]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[188]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[239]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[240]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[107]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[48]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[96]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[46]
THAPSIGARGIN	DMDMQIE	N. A.	N. A.	Preclinical	[241]

Drug(s) Affected By Kinectin (KTN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[48]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[242]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Benzatropine	DMF7EXL	Parkinsonian disorder		Approved	[201]
Bortezomib	DMNO38U	Leukemia		Approved	[57]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[61]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[243]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[48]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[244]

Drug(s) Affected By Cerebellin-2 (CBLN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[22]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[65]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[66]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[66]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[102]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[43]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[100]
THAPSIGARGIN	DMDMQIE	N. A.	N. A.	Preclinical	[241]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[186]

Drug(s) Affected By GRIP and coiled-coil domain-containing protein 2 (GCC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[22]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[187]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[201]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[60]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[100]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[50]

Drug(s) Affected By DnaJ homolog subfamily C member 10 (DNAJC10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[245]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[242]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[58]
Atazanavir	DMSYRBX	Human immunodeficiency virus infection	1C62	Approved	[245]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[58]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[206]

Drug(s) Affected By Copine-9 (CPNE9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[78]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[100]

Drug(s) Affected By Serine/threonine-protein kinase PDIK1L (PDIK1L)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[226]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[44]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[186]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[204]

Drug(s) Affected By Cohesin subunit SA-2 (STAG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[48]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[144]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[239]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[60]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[43]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[48]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[100]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[46]

Drug(s) Affected By Testis-expressed protein 9 (TEX9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[71]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[98]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[158]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[246]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[64]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[50]
OXYQUINOLINE	DMZVS9Y	Discovery agent	N.A.	Investigative	[20]

Drug(s) Affected By Kelch domain-containing protein 1 (KLHDC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[49]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[68]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[40]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[226]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[47]

Drug(s) Affected By Cytoplasmic dynein 2 heavy chain 1 (DYNC2H1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[229]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[43]
Fenfluramine	DM0762O	Dravet syndrome	8A61.11	Phase 3	[184]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[103]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[186]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[47]

Drug(s) Affected By Coiled-coil domain-containing protein 112 (CCDC112)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[53]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[247]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[99]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[100]

Drug(s) Affected By Biorientation of chromosomes in cell division protein 1-like 1 (BOD1L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[45]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[45]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[52]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[198]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[43]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[46]
Geldanamycin	DMS7TC5	Kidney cancer	2C90.0	Discontinued in Phase 2	[45]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[46]
methyl p-hydroxybenzoate	DMO58UW	Discovery agent	N.A.	Investigative	[248]

Drug(s) Affected By Metalloreductase STEAP2 (STEAP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[186]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[249]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[75]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[53]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[250]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[43]

Drug(s) Affected By Motile sperm domain-containing protein 2 (MOSPD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[251]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[251]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[158]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[100]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[44]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[142]

Drug(s) Affected By Centrosomal protein of 70 kDa (CEP70)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[49]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[158]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[43]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[99]

Drug(s) Affected By TBC1 domain family member 15 (TBC1D15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[49]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[252]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[199]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[185]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[100]

Drug(s) Affected By Cytoplasmic dynein 2 light intermediate chain 1 (DYNC2LI1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[195]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[251]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[251]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[40]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[199]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[250]

Drug(s) Affected By Mirror-image polydactyly gene 1 protein (MIPOL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[124]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[68]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[106]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[75]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[53]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[99]
PEITC	DMOMN31	Prostate cancer	2C82.0	Phase 2	[253]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]

Drug(s) Affected By Glucosamine-6-phosphate isomerase 2 (GNPDA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[254]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[74]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[68]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[40]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[199]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[99]

Drug(s) Affected By RB1-inducible coiled-coil protein 1 (RB1CC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trovafloxacin	DM6AN32	Acute gonococcal cervicitis		Approved	[255]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[68]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[256]
Bortezomib	DMNO38U	Leukemia		Approved	[57]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[131]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[257]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[99]

Drug(s) Affected By PH-interacting protein (PHIP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[258]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[64]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[259]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[83]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[96]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[46]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[46]

Drug(s) Affected By Cholesterol transporter ABCA5 (ABCA5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[71]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[64]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[260]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[261]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[40]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[206]

Drug(s) Affected By Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 2 (ARAP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[64]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[74]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[66]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[50]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[98]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[53]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[199]

Drug(s) Affected By Rap guanine nucleotide exchange factor 4 (RAPGEF4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[71]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[25]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[199]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[26]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[262]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[263]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[44]
3R14S-OCHRATOXIN A	DM2KEW6	Discovery agent	N.A.	Investigative	[263]

Drug(s) Affected By PHD finger protein 3 (PHF3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[48]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[46]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[68]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[93]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[82]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[183]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[185]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[48]

Drug(s) Affected By DNA repair protein RAD50 (RAD50)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[173]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[264]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[265]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[79]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[266]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[93]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]

Drug(s) Affected By Cysteine protease ATG4C (ATG4C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[100]

Drug(s) Affected By Protein-L-isoaspartate O-methyltransferase domain-containing protein 1 (PCMTD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[124]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[267]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[147]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[41]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[43]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[99]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[64]

Drug(s) Affected By Melanoma inhibitory activity protein 2 (MIA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[150]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[68]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[150]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[140]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[44]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[46]

Drug(s) Affected By NudC domain-containing protein 1 (NUDCD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[65]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[40]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[41]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[43]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[185]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[106]

Drug(s) Affected By Protein SCAF11 (SCAF11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[46]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[235]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[69]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[93]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[50]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[60]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[268]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[183]

Drug(s) Affected By RANBP2-like and GRIP domain-containing protein 5/6 (RGPD6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[174]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[187]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[65]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[269]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[46]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[204]
methyl p-hydroxybenzoate	DMO58UW	Discovery agent	N.A.	Investigative	[248]

Drug(s) Affected By Semaphorin-3C (SEMA3C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[186]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[222]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[21]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[22]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[64]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[65]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[270]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[52]

Drug(s) Affected By A-kinase anchor protein 9 (AKAP9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[79]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[49]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[50]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[161]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[202]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[60]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[41]

Drug(s) Affected By Sentrin-specific protease 7 (SENP7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[188]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[53]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[199]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[250]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[64]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[44]

Drug(s) Affected By Transcription elongation factor A protein-like 7 (TCEAL7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[75]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[247]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[109]

Drug(s) Affected By Electrogenic sodium bicarbonate cotransporter 4 (SLC4A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[271]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[78]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[186]

Drug(s) Affected By Lactosylceramide 1,3-N-acetyl-beta-D-glucosaminyltransferase (B3GNT5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[161]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[50]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[82]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[53]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[61]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[77]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]

Drug(s) Affected By Sentrin-specific protease 6 (SENP6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[272]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[52]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[60]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[203]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[272]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[96]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[208]

Drug(s) Affected By Nuclear speckle splicing regulatory protein 1 (NSRP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[185]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[96]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[100]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[46]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[46]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[142]

Drug(s) Affected By THAP domain-containing protein 2 (THAP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[53]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[41]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[99]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[273]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[64]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[208]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[204]

Drug(s) Affected By Cadherin-23 (CDH23)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[49]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[274]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[100]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[275]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[47]

Drug(s) Affected By STE20-like serine/threonine-protein kinase (SLK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[41]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[185]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[276]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[277]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[46]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[46]

Drug(s) Affected By SLIT and NTRK-like protein 6 (SLITRK6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[22]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[64]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[41]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[64]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[206]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[186]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[142]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[47]

Drug(s) Affected By tRNA (NSUN3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[124]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[68]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[40]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[99]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[244]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[44]
RESORCINOL	DMM37C0	Discovery agent	N.A.	Investigative	[98]

Drug(s) Affected By 5-azacytidine-induced protein 2 (AZI2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[209]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[44]
PMID28870136-Compound-48	DMPIM9L	N. A.	N. A.	Patented	[173]
3R14S-OCHRATOXIN A	DM2KEW6	Discovery agent	N.A.	Investigative	[278]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[50]

Drug(s) Affected By Frizzled-3 (FZD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[124]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[71]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[64]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[75]
Adenosine	DMM2NSK	Paroxysmal supraventricular tachycardia	BC81.Z	Approved	[279]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[58]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[40]

Drug(s) Affected By Adenosine 5'-monophosphoramidase HINT3 (HINT3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[161]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[47]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[50]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[140]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[185]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[44]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[280]

Drug(s) Affected By Bromodomain and WD repeat-containing protein 1 (BRWD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[173]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[22]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[188]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[61]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[43]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[281]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[46]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[46]

Drug(s) Affected By Ethylmalonyl-CoA decarboxylase (ECHDC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[90]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[282]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[106]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[100]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[186]

Drug(s) Affected By Transmembrane protein 106B (TMEM106B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[173]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[235]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[66]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[66]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[43]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[100]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[46]

Drug(s) Affected By NEDD4 family-interacting protein 2 (NDFIP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[71]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[75]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[251]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[198]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[172]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[206]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[99]

Drug(s) Affected By Contactin-3 (CNTN3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[45]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[60]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[77]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[102]
PDX-101	DM6OC53	Plasma cell myeloma	2A83.1	Phase 2	[64]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[47]

Drug(s) Affected By Inhibitor of Bruton tyrosine kinase (IBTK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[46]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[224]
Bortezomib	DMNO38U	Leukemia		Approved	[57]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[283]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[60]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[185]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[100]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[46]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[46]

Drug(s) Affected By Intraflagellar transport protein 80 homolog (IFT80)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[40]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[60]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[43]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[26]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[44]

Drug(s) Affected By DNA polymerase kappa (POLK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[284]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[52]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[53]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Guanine	DMIWLJE	N. A.	N. A.	Phase 3	[285]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[96]
MK-886	DMT0O7H	Asthma	CA23	Discontinued in Phase 2	[286]
680C91	DMCDTIG	Solid tumour/cancer	2A00-2F9Z	Preclinical	[287]

Drug(s) Affected By Hydroxyproline dehydrogenase (PRODH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[158]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[288]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[289]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[102]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[99]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[274]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[226]

Drug(s) Affected By Bromodomain adjacent to zinc finger domain protein 2B (BAZ2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[22]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[175]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[53]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[41]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[64]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[100]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[46]

Drug(s) Affected By Dickkopf-like protein 1 (DKKL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[56]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[290]
Fenfluramine	DM0762O	Dravet syndrome	8A61.11	Phase 3	[184]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[103]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[44]

Drug(s) Affected By A-kinase anchor protein 11 (AKAP11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[90]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[81]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[198]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[60]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[250]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[43]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[99]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[100]

Drug(s) Affected By Protein BCAP (ODF2L)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[22]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[74]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[68]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[78]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[100]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[44]
Torcetrapib	DMDHYM7	Hyperlipidaemia	5C80	Discontinued in Phase 2	[291]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[186]

Drug(s) Affected By Unconventional myosin-VI (MYO6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[48]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[71]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[292]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[181]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[75]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[53]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[158]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]

Drug(s) Affected By Leucine-rich repeat protein SHOC-2 (SHOC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[161]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]
4-hydroxy-2-nonenal	DM2LJFZ	Discovery agent	N.A.	Investigative	[143]

Drug(s) Affected By Tyrosine-protein phosphatase non-receptor type 22 (PTPN22)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[173]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[73]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[293]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[294]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[75]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[148]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[92]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[40]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[250]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[108]

Drug(s) Affected By Transmembrane emp24 domain-containing protein 5 (TMED5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[90]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[64]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[26]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[27]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[53]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[199]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[43]
Sodium phenylbutyrate	DMXLBCQ	Spinal muscular atrophy	8B61	Approved	[295]

Drug(s) Affected By DmX-like protein 1 (DMXL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[20]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[296]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[297]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[296]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[80]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[147]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[39]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[53]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[60]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[42]

Drug(s) Affected By Solute carrier organic anion transporter family member 1B1 (SLCO1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Enalapril	DMNFUZR	Congestive heart failure	BD10	Approved	[298]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[299]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[300]
Repaglinide	DM5SXUV	Diabetic complication	5A2Y	Approved	[301]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[302]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[303]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[304]
Ursodeoxycholic acid	DMCUT21	Cholelithiasis	DC11	Approved	[304]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[305]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[306]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Monoamine oxidase (MAO)	TT32XQJ	NOUNIPROTAC	Inhibitor	[2]
Monoamine oxidase type A (MAO-A)	TT3WG5C	AOFA_HUMAN	Inhibitor	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
5'-nucleotidase domain-containing protein 1 (NT5DC1)	OTNI9MFH	NT5D1_HUMAN	Gene/Protein Processing	[4]
5-azacytidine-induced protein 2 (AZI2)	OT61Q7Q8	AZI2_HUMAN	Gene/Protein Processing	[4]
A-kinase anchor protein 11 (AKAP11)	OT7E2FVD	AKA11_HUMAN	Gene/Protein Processing	[4]
A-kinase anchor protein 9 (AKAP9)	OT7Z2YRP	AKAP9_HUMAN	Gene/Protein Processing	[4]
Adenomatous polyposis coli protein (APC)	OTKV0TIK	APC_HUMAN	Gene/Protein Processing	[4]
Adenosine 5'-monophosphoramidase HINT3 (HINT3)	OTJGDLB6	HINT3_HUMAN	Gene/Protein Processing	[4]
Amine oxidase A (MAOA)	OT8NIWMQ	AOFA_HUMAN	Gene/Protein Processing	[5]
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Gene/Protein Processing	[4]
Ankyrin repeat domain-containing protein 12 (ANKRD12)	OTK16BL9	ANR12_HUMAN	Gene/Protein Processing	[4]
Arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 2 (ACAP2)	OTYNZPC4	ACAP2_HUMAN	Gene/Protein Processing	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6636).
• [2] Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
• [3] Further investigation into the mechanism of tachykinin NK(2) receptor-triggered serotonin release from guinea-pig proximal colon. J Pharmacol Sci. 2009 May;110(1):122-6.
• [4] Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics. 2009 Aug 20;2:55. doi: 10.1186/1755-8794-2-55.
• [5] Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors. J Med Chem. 2011 Oct 27;54(20):7127-37.
• [6] Photoluminescence of CdTe nanocrystals modulated by methylene blue and DNA. A label-free luminescent signaling nanohybrid platform. Phys Chem Chem Phys. 2009 Jul 7;11(25):5062-9.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [8] LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
• [9] Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002 Dec;17(8):401-5.
• [10] Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. Int J Neuropsychopharmacol. 2009 Mar 11:1-11.
• [11] MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219.
• [12] Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
• [13] Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80.
• [14] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [15] Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.
• [16] Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology. 2010 Feb;35(3):623-31.
• [17] Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40.
• [18] Phase I clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: tolerance and pharmacokinetics study of escalating single oral doses. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):141-7.
• [19] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [20] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [21] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [22] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [23] Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
• [24] Characterizing fucoxanthin as a selective dopamine D(3)/D(4) receptor agonist: Relevance to Parkinson's disease. Chem Biol Interact. 2019 Sep 1;310:108757. doi: 10.1016/j.cbi.2019.108757. Epub 2019 Jul 16.
• [25] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [26] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [27] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [28] Combining initro and in silico approaches to evaluate the multifunctional profile of rosmarinic acid from Blechnum brasiliense on targets related to neurodegeneration. Chem Biol Interact. 2016 Jul 25;254:135-45.
• [29] Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
• [30] Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes. Chem Biol Interact. 2016 Aug 5;255:31-44.
• [31] Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
• [32] Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of the pregnane X receptor. Chem Res Toxicol. 2014 Feb 17;27(2):304-308.
• [33] Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem. 2004 Jul 9;279(28):29295-301. doi: 10.1074/jbc.M400580200. Epub 2004 Apr 28.
• [34] Identification of novel agonists by high-throughput screening and molecular modelling of human constitutive androstane receptor isoform 3. Arch Toxicol. 2019 Aug;93(8):2247-2264. doi: 10.1007/s00204-019-02495-6. Epub 2019 Jul 16.
• [35] Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2005 Jun;67(6):1954-65.
• [36] Characterization of human cytochrome P450 induction by pesticides. Toxicology. 2012 Mar 29;294(1):17-26.
• [37] Species-specific mechanisms for cholesterol 7alpha-hydroxylase (CYP7A1) regulation by drugs and bile acids. Arch Biochem Biophys. 2005 Feb 1;434(1):75-85.
• [38] Pyrethroids: cytotoxicity and induction of CYP isoforms in human hepatocytes. Drug Metabol Drug Interact. 2008;23(3-4):211-36.
• [39] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [40] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [41] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [42] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [43] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [44] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [45] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [46] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [47] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [48] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [49] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [50] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [51] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [52] Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
• [53] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [54] Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res. 2006 Mar 1;66(5):2765-77.
• [55] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [56] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [57] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [58] Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNF-mediated hepatotoxicity. Toxicol Sci. 2014 Jul;140(1):144-59. doi: 10.1093/toxsci/kfu072. Epub 2014 Apr 20.
• [59] Novel carbocyclic curcumin analog CUR3d modulates genes involved in multiple apoptosis pathways in human hepatocellular carcinoma cells. Chem Biol Interact. 2015 Dec 5;242:107-22.
• [60] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [61] Pleiotropic combinatorial transcriptomes of human breast cancer cells exposed to mixtures of dietary phytoestrogens. Food Chem Toxicol. 2009 Apr;47(4):787-95.
• [62] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [63] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [64] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [65] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [66] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [67] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [68] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [69] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [70] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [71] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [72] Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
• [73] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [74] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [75] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [76] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [77] Effects of progesterone treatment on expression of genes involved in uterine quiescence. Reprod Sci. 2011 Aug;18(8):781-97.
• [78] Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro. Int J Mol Sci. 2023 Mar 26;24(7):6259. doi: 10.3390/ijms24076259.
• [79] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [80] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [81] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [82] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [83] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [84] Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
• [85] Induction of PXR-mediated metabolism by beta-carotene. Biochim Biophys Acta. 2005 May 30;1740(2):162-9. doi: 10.1016/j.bbadis.2004.11.013. Epub 2004 Dec 8.
• [86] Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol Appl Pharmacol. 2005 Dec 1;209(2):123-33. doi: 10.1016/j.taap.2005.03.015.
• [87] Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos. 2011 Feb;39(2):337-44. doi: 10.1124/dmd.110.035808. Epub 2010 Nov 10.
• [88] Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
• [89] Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor. Toxicol Lett. 2017 Jan 4;265:86-96.
• [90] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [91] Testosterone and prolactin increase carboxypeptidase-D and nitric oxide levels to promote survival of prostate cancer cells. Prostate. 2012 Mar;72(4):450-60.
• [92] Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
• [93] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [94] Phosphoproteomics reveals resveratrol-dependent inhibition of Akt/mTORC1/S6K1 signaling. J Proteome Res. 2014 Dec 5;13(12):5734-42. doi: 10.1021/pr500714a. Epub 2014 Oct 29.
• [95] Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein. Neoplasia. 2004 Jul-Aug;6(4):354-63. doi: 10.1593/neo.03478.
• [96] Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
• [97] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [98] A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
• [99] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [100] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [101] Chronic ethanol exposure increases goosecoid (GSC) expression in human embryonic carcinoma cell differentiation. J Appl Toxicol. 2014 Jan;34(1):66-75.
• [102] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [103] Benzo[a]pyrene-induced changes in microRNA-mRNA networks. Chem Res Toxicol. 2012 Apr 16;25(4):838-49.
• [104] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [105] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [106] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [107] Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer. BMC Cancer. 2007 Dec 11;7:223.
• [108] BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011 Sep 16;146(6):904-17.
• [109] Bisphenol A induces DSB-ATM-p53 signaling leading to cell cycle arrest, senescence, autophagy, stress response, and estrogen release in human fetal lung fibroblasts. Arch Toxicol. 2018 Apr;92(4):1453-1469.
• [110] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [111] Effects of natural products and nutraceuticals on steroid hormone-regulated gene expression. Clin Chim Acta. 2001 Oct;312(1-2):213-9. doi: 10.1016/s0009-8981(01)00626-x.
• [112] Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res. 2004 Jan 1;64(1):19-22. doi: 10.1158/0008-5472.can-03-2789.
• [113] Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 2001 Mar;22(3):409-14. doi: 10.1093/carcin/22.3.409.
• [114] EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. Oncotarget. 2015 Feb 28;6(6):3811-24.
• [115] Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells. Prostate. 2007 Aug 1;67(11):1152-62. doi: 10.1002/pros.20585.
• [116] Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo. Prostate. 2009 May 15;69(7):744-54. doi: 10.1002/pros.20923.
• [117] An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer. 2003 Mar 24;88(6):822-7. doi: 10.1038/sj.bjc.6600817.
• [118] Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate. 2010 Oct 1;70(14):1575-85. doi: 10.1002/pros.21193.
• [119] Pleiotropic beta-agonist-promoted receptor conformations and signals independent of intrinsic activity. Am J Respir Cell Mol Biol. 2007 Feb;36(2):236-43. doi: 10.1165/rcmb.2006-0257OC. Epub 2006 Sep 15.
• [120] Development of 3D-QSAR models for predicting the activities of chemicals to stimulate muscle growth via (2)-adrenoceptor. Toxicol In Vitro. 2021 Dec;77:105251. doi: 10.1016/j.tiv.2021.105251. Epub 2021 Sep 30.
• [121] Beta2-adrenergic receptor polymorphisms in African American children with status asthmaticus. Pediatr Crit Care Med. 2006 Jan;7(1):15-8. doi: 10.1097/01.pcc.0000194010.63115.a2.
• [122] beta2-adrenergic receptor polymorphisms and salbutamol-stimulated energy expenditure. J Clin Endocrinol Metab. 2005 Apr;90(4):2301-7. doi: 10.1210/jc.2004-1356. Epub 2005 Feb 1.
• [123] Neutrophil beta(2)-adrenoceptor function in major depression: G(s) coupling, effects of imipramine and relationship to treatment outcome. Eur J Pharmacol. 1999 Dec 15;386(2-3):135-44. doi: 10.1016/s0014-2999(99)00749-9.
• [124] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [125] Myocardial ischaemia and ventricular arrhthymias precipitated by physiological concentrations of adrenaline in patients with coronary artery disease. Br Heart J. 1992 May;67(5):419-20. doi: 10.1136/hrt.67.5.419-b.
• [126] Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Prostate. 2008 Jul 1;68(10):1133-42. doi: 10.1002/pros.20778.
• [127] Histamine augments beta2-adrenoceptor-induced cyclic AMP accumulation in human prostate cancer cells DU-145 independently of known histamine receptors. Biochem Pharmacol. 2007 Mar 15;73(6):814-23. doi: 10.1016/j.bcp.2006.11.022. Epub 2006 Dec 1.
• [128] Cardiac toxicity from ethanol exposure in human-induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci. 2019 May 1;169(1):280-292.
• [129] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [130] Effects of olanzapine on serum protein phosphorylation patterns in patients with schizophrenia. Proteomics Clin Appl. 2015 Oct;9(9-10):907-16. doi: 10.1002/prca.201400148. Epub 2015 May 15.
• [131] Gene expression data from acetaminophen-induced toxicity in human hepatic in vitro systems and clinical liver samples. Data Brief. 2016 Mar 26;7:1052-1057. doi: 10.1016/j.dib.2016.03.069. eCollection 2016 Jun.
• [132] Unique transcriptome, pathways, and networks in the human endometrial fibroblast response to progesterone in endometriosis. Biol Reprod. 2011 Apr;84(4):801-15.
• [133] TBECH, 1,2-dibromo-4-(1,2 dibromoethyl) cyclohexane, alters androgen receptor regulation in response to mutations associated with prostate cancer. Toxicol Appl Pharmacol. 2016 Sep 15;307:91-101. doi: 10.1016/j.taap.2016.07.018. Epub 2016 Jul 27.
• [134] Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res. 2015 Jul 13;43(12):5880-97. doi: 10.1093/nar/gkv262. Epub 2015 Apr 23.
• [135] Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells. Prostate. 2005 Nov 1;65(3):268-75. doi: 10.1002/pros.20282.
• [136] Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7. J Steroid Biochem Mol Biol. 2002 Jan;80(1):61-70. doi: 10.1016/s0960-0760(01)00173-x.
• [137] Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform. Toxicology. 2017 Jun 15;385:48-58. doi: 10.1016/j.tox.2017.05.001. Epub 2017 May 4.
• [138] Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
• [139] Comparison of the Hershberger assay and androgen receptor binding assay of twelve chemicals. Toxicology. 2004 Feb 15;195(2-3):177-86. doi: 10.1016/j.tox.2003.09.012.
• [140] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [141] Involvement of the Endocrine-Disrupting Chemical Bisphenol A (BPA) in Human Placentation. J Clin Med. 2020 Feb 3;9(2):405. doi: 10.3390/jcm9020405.
• [142] Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
• [143] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [144] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [145] Folic acid enforces DNA methylation-mediated transcriptional silencing of PTEN, APC and RARbeta2 tumour suppressor genes in breast cancer. Biochem Biophys Res Commun. 2013 Jan 11;430(2):623-8. doi: 10.1016/j.bbrc.2012.11.103. Epub 2012 Dec 3.
• [146] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [147] Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
• [148] In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
• [149] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [150] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [151] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [152] Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. Biol Chem. 2006 Dec;387(12):1629-33. doi: 10.1515/BC.2006.203.
• [153] Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: modulation of Fas/Fas ligand and caspase-3 pathway. Cardiovasc Res. 2000 Feb;45(3):788-94. doi: 10.1016/s0008-6363(99)00369-7.
• [154] Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
• [155] Regulatory role of KEAP1 and NRF2 in PPAR expression and chemoresistance in human non-small-cell lung carcinoma cells. Free Radic Biol Med. 2012 Aug 15;53(4):758-68. doi: 10.1016/j.freeradbiomed.2012.05.041. Epub 2012 Jun 7.
• [156] Non-nutritional sweeteners effects on endothelial vascular function. Toxicol In Vitro. 2020 Feb;62:104694. doi: 10.1016/j.tiv.2019.104694. Epub 2019 Oct 23.
• [157] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
• [158] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [159] Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets. Int J Cancer. 2003 Mar 20;104(2):204-12.
• [160] Transcriptional up-regulation of restin by all-trans retinoic acid through STAT1 in cancer cell differentiation process. Biochem Biophys Res Commun. 2006 May 19;343(4):1009-16. doi: 10.1016/j.bbrc.2006.02.176. Epub 2006 Mar 9.
• [161] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [162] Gene expression in human hippocampus from cocaine abusers identifies genes which regulate extracellular matrix remodeling. PLoS One. 2007 Nov 14;2(11):e1187. doi: 10.1371/journal.pone.0001187.
• [163] High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy. Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):2058-63.
• [164] Gamma-irradiation and doxorubicin treatment of normal human cells cause cell cycle arrest via different pathways. Mol Cells. 2005 Dec 31;20(3):331-8.
• [165] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [166] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [167] The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009 Jun;23(6):1019-28.
• [168] Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clin Cancer Res. 2009 May 15;15(10):3406-15. doi: 10.1158/1078-0432.CCR-08-2099. Epub 2009 Apr 28.
• [169] Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103. Cytotherapy. 2011 May;13(5):618-28. doi: 10.3109/14653249.2010.529893. Epub 2010 Dec 20.
• [170] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [171] Chenodeoxycholic acid significantly impacts the expression of miRNAs and genes involved in lipid, bile acid and drug metabolism in human hepatocytes. Life Sci. 2016 Jul 1;156:47-56.
• [172] Increased mitochondrial ROS formation by acetaminophen in human hepatic cells is associated with gene expression changes suggesting disruption of the mitochondrial electron transport chain. Toxicol Lett. 2015 Apr 16;234(2):139-50.
• [173] Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
• [174] Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):333-40.
• [175] Gene expression signatures after ethanol exposure in differentiating embryoid bodies. Toxicol In Vitro. 2018 Feb;46:66-76.
• [176] PPARgamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells. J Exp Med. 2006 Oct 2;203(10):2351-62.
• [177] Regulation of Hepatic Cholesteryl Ester Transfer Protein Expression and Reverse Cholesterol Transport by Inhibition of DNA Topoisomerase II. J Biol Chem. 2015 Jun 5;290(23):14418-29. doi: 10.1074/jbc.M115.643015. Epub 2015 Apr 25.
• [178] Gene expression profiling in Ishikawa cells: a fingerprint for estrogen active compounds. Toxicol Appl Pharmacol. 2009 Apr 1;236(1):85-96.
• [179] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [180] JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
• [181] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [182] Curcumin prevents DNA damage and enhances the repair potential in a chronically arsenic-exposed human population in West Bengal, India. Eur J Cancer Prev. 2011 Mar;20(2):123-31. doi: 10.1097/cej.0b013e328341017a.
• [183] Nicotinic modulation of gene expression in SH-SY5Y neuroblastoma cells. Brain Res. 2006 Oct 20;1116(1):39-49.
• [184] Fenfluramine-induced gene dysregulation in human pulmonary artery smooth muscle and endothelial cells. Pulm Circ. 2011 Jul-Sep;1(3):405-18. doi: 10.4103/2045-8932.87310.
• [185] Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
• [186] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [187] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [188] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [189] Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies. Leuk Res. 2008 Feb;32(2):275-85. doi: 10.1016/j.leukres.2007.05.024. Epub 2007 Jul 19.
• [190] Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
• [191] Involvement of p38 MAPK and Nrf2 in phenolic acid-induced P-form phenol sulfotransferase expression in human hepatoma HepG2 cells. Carcinogenesis. 2006 May;27(5):1008-17.
• [192] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [193] Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment. J Pharmacol Exp Ther. 2014 Mar;348(3):360-71. doi: 10.1124/jpet.113.210054. Epub 2013 Dec 17.
• [194] Progesterone and calcitriol attenuate inflammatory cytokines CXCL1 and CXCL2 in ovarian and endometrial cancer cells. J Cell Biochem. 2012 Oct;113(10):3143-52. doi: 10.1002/jcb.24191.
• [195] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [196] Gene expression profile of human lymphoid CEM cells sensitive and resistant to glucocorticoid-evoked apoptosis. Genomics. 2003 Jun;81(6):543-55.
• [197] Reactive oxygen species mediate chloroquine-induced expression of chemokines by human astroglial cells. Glia. 2004 Jul;47(1):9-20. doi: 10.1002/glia.20017.
• [198] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [199] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [200] Persistent and non-persistent changes in gene expression result from long-term estrogen exposure of MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 2011 Feb;123(3-5):140-50.
• [201] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [202] Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population. Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1367-75. doi: 10.1158/1055-9965.EPI-06-0106.
• [203] A genomic approach to predict synergistic combinations for breast cancer treatment. Pharmacogenomics J. 2013 Feb;13(1):94-104. doi: 10.1038/tpj.2011.48. Epub 2011 Nov 15.
• [204] Gene expression changes in primary human nasal epithelial cells exposed to formaldehyde in vitro. Toxicol Lett. 2010 Oct 5;198(2):289-95.
• [205] A trichostatin A expression signature identified by TempO-Seq targeted whole transcriptome profiling. PLoS One. 2017 May 25;12(5):e0178302. doi: 10.1371/journal.pone.0178302. eCollection 2017.
• [206] LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
• [207] Proteomic analysis of the cellular response to a potent sensitiser unveils the dynamics of haptenation in living cells. Toxicology. 2020 Dec 1;445:152603. doi: 10.1016/j.tox.2020.152603. Epub 2020 Sep 28.
• [208] Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol Sci. 2010 Apr;114(2):247-59.
• [209] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [210] Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2. Biochem Pharmacol. 2011 Feb 15;81(4):510-7. doi: 10.1016/j.bcp.2010.11.014. Epub 2010 Nov 27.
• [211] Differential responses to retinoic acid and endocrine disruptor compounds of subpopulations within human embryonic stem cell lines. Differentiation. 2012 Nov;84(4):330-43. doi: 10.1016/j.diff.2012.07.006. Epub 2012 Aug 18.
• [212] Interaction of EZH2 and P65 is involved in the arsenic trioxide-induced anti-angiogenesis in human triple-negative breast cancer cells. Cell Biol Toxicol. 2019 Aug;35(4):361-371. doi: 10.1007/s10565-018-09458-0. Epub 2019 Jan 5.
• [213] In vitro hydroquinone-induced instauration of histone bivalent mark on human retroelements (LINE-1) in HL60 cells. Toxicol In Vitro. 2017 Apr;40:1-10. doi: 10.1016/j.tiv.2016.12.007. Epub 2016 Dec 13.
• [214] Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis. J Cell Biochem. 2017 Apr;118(4):819-828. doi: 10.1002/jcb.25757. Epub 2016 Nov 28.
• [215] Protective role of HO-1 for alcohol-dependent liver damage. Dig Dis. 2010;28(6):792-8. doi: 10.1159/000324287. Epub 2011 Apr 27.
• [216] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [217] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [218] Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease. J Neurosci. 2016 Jun 8;36(23):6332-51. doi: 10.1523/JNEUROSCI.0426-16.2016.
• [219] Simvastatin protects dopaminergic neurons against MPP+-induced oxidative stress and regulates the endogenous anti-oxidant system through ERK. Cell Physiol Biochem. 2018;51(4):1957-1968.
• [220] P450 3A-catalyzed O-dealkylation of lapatinib induces mitochondrial stress and activates Nrf2. Chem Res Toxicol. 2016 May 16;29(5):784-96.
• [221] P21(Waf1/Cip1) plays a critical role in furazolidone-induced apoptosis in HepG2 cells through influencing the caspase-3 activation and ROS generation. Food Chem Toxicol. 2016 Feb;88:1-12. doi: 10.1016/j.fct.2015.12.004. Epub 2015 Dec 11.
• [222] Hypoxia-inducible factor-1 (HIF-1) pathway activation by quercetin in human lens epithelial cells. Exp Eye Res. 2009 Dec;89(6):995-1002. doi: 10.1016/j.exer.2009.08.011. Epub 2009 Sep 1.
• [223] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [224] CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
• [225] Substance dependence low-density whole genome association study in two distinct American populations. Hum Genet. 2008 Jun;123(5):495-506. doi: 10.1007/s00439-008-0501-0. Epub 2008 Apr 26.
• [226] Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
• [227] New insights into BaP-induced toxicity: role of major metabolites in transcriptomics and contribution to hepatocarcinogenesis. Arch Toxicol. 2016 Jun;90(6):1449-58.
• [228] Evaluation of estrogen receptor alpha activation by glyphosate-based herbicide constituents. Food Chem Toxicol. 2017 Oct;108(Pt A):30-42.
• [229] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [230] The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. Toxicol Sci. 2009 Jan;107(1):40-55.
• [231] Isobaric tags for relative and absolute quantitation-based proteomics analysis of the effect of ginger oil on bisphenol A-induced breast cancer cell proliferation. Oncol Lett. 2021 Feb;21(2):101. doi: 10.3892/ol.2020.12362. Epub 2020 Dec 8.
• [232] Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2730-5. doi: 10.1073/pnas.1018872108. Epub 2011 Apr 11.
• [233] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [234] The human myometrium differentially expresses mTOR signalling components before and during pregnancy: evidence for regulation by progesterone. J Steroid Biochem Mol Biol. 2014 Jan;139:166-72. doi: 10.1016/j.jsbmb.2013.02.017. Epub 2013 Mar 26.
• [235] Delta9-tetrahydrocannabinol inhibits cytotrophoblast cell proliferation and modulates gene transcription. Mol Hum Reprod. 2006 May;12(5):321-33. doi: 10.1093/molehr/gal036. Epub 2006 Apr 5.
• [236] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [237] Alternatives for the worse: Molecular insights into adverse effects of bisphenol a and substitutes during human adipocyte differentiation. Environ Int. 2021 Nov;156:106730. doi: 10.1016/j.envint.2021.106730. Epub 2021 Jun 27.
• [238] Gene expression profile and cytotoxicity of human bronchial epithelial cells exposed to crotonaldehyde. Toxicol Lett. 2010 Aug 16;197(2):113-22.
• [239] Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity. Arch Toxicol. 2018 Jan;92(1):469-485.
• [240] Epigenetic changes in individuals with arsenicosis. Chem Res Toxicol. 2011 Feb 18;24(2):165-7. doi: 10.1021/tx1004419. Epub 2011 Feb 4.
• [241] Endoplasmic reticulum stress impairs insulin signaling through mitochondrial damage in SH-SY5Y cells. Neurosignals. 2012;20(4):265-80.
• [242] Proteomics-based identification of differentially abundant proteins from human keratinocytes exposed to arsenic trioxide. J Proteomics Bioinform. 2014 Jul;7(7):166-178.
• [243] Expression Profiling of Human Pluripotent Stem Cell-Derived Cardiomyocytes Exposed to Doxorubicin-Integration and Visualization of Multi-Omics Data. Toxicol Sci. 2018 May 1;163(1):182-195. doi: 10.1093/toxsci/kfy012.
• [244] Effect of aflatoxin B(1), benzo[a]pyrene, and methapyrilene on transcriptomic and epigenetic alterations in human liver HepaRG cells. Food Chem Toxicol. 2018 Nov;121:214-223. doi: 10.1016/j.fct.2018.08.034. Epub 2018 Aug 26.
• [245] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [246] RNA sequence analysis of inducible pluripotent stem cell-derived cardiomyocytes reveals altered expression of DNA damage and cell cycle genes in response to doxorubicin. Toxicol Appl Pharmacol. 2018 Oct 1;356:44-53.
• [247] Cytosine arabinoside induces ectoderm and inhibits mesoderm expression in human embryonic stem cells during multilineage differentiation. Br J Pharmacol. 2011 Apr;162(8):1743-56.
• [248] Transcriptome dynamics of alternative splicing events revealed early phase of apoptosis induced by methylparaben in H1299 human lung carcinoma cells. Arch Toxicol. 2020 Jan;94(1):127-140. doi: 10.1007/s00204-019-02629-w. Epub 2019 Nov 20.
• [249] In vitro assessment of drug-induced liver steatosis based on human dermal stem cell-derived hepatic cells. Arch Toxicol. 2016 Mar;90(3):677-89. doi: 10.1007/s00204-015-1483-z. Epub 2015 Feb 26.
• [250] Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One. 2012;7(5):e36711. doi: 10.1371/journal.pone.0036711. Epub 2012 May 4.
• [251] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [252] Toxicoproteomics reveals an effect of clozapine on autophagy in human liver spheroids. Toxicol Mech Methods. 2023 Jun;33(5):401-410. doi: 10.1080/15376516.2022.2156005. Epub 2022 Dec 19.
• [253] Identification of potential protein targets of isothiocyanates by proteomics. Chem Res Toxicol. 2011 Oct 17;24(10):1735-43. doi: 10.1021/tx2002806. Epub 2011 Aug 26.
• [254] Epigenetic activation of O-linked -N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia. EBioMedicine. 2020 Apr;54:102678. doi: 10.1016/j.ebiom.2020.102678. Epub 2020 Apr 6.
• [255] TNF enhances trovafloxacin-induced in vitro hepatotoxicity by inhibiting protective autophagy. Toxicol Lett. 2021 May 15;342:73-84. doi: 10.1016/j.toxlet.2021.02.009. Epub 2021 Feb 17.
• [256] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [257] Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
• [258] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [259] Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. PLoS One. 2011;6(8):e23569.
• [260] Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head Neck. 2011 Jul;33(7):959-68. doi: 10.1002/hed.21559. Epub 2010 Aug 24.
• [261] Expression of copper-responsive genes in HepG2 cells. Mol Cell Biochem. 2005 Nov;279(1-2):141-7.
• [262] Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
• [263] Inhibition of CXCL12-mediated chemotaxis of Jurkat cells by direct immunotoxicants. Arch Toxicol. 2016 Jul;90(7):1685-94. doi: 10.1007/s00204-015-1585-7. Epub 2015 Aug 28.
• [264] Identification of biomarkers for the initiation of apoptosis in human preneoplastic colonocytes by proteome analysis. Int J Cancer. 2004 Mar 20;109(2):220-9. doi: 10.1002/ijc.11692.
• [265] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [266] Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
• [267] Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
• [268] Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta. Mol Biol Cell. 2004 Mar;15(3):1262-72. doi: 10.1091/mbc.e03-06-0360. Epub 2003 Dec 29.
• [269] High-throughput data integration of RNA-miRNA-circRNA reveals novel insights into mechanisms of benzo[a]pyrene-induced carcinogenicity. Nucleic Acids Res. 2015 Mar 11;43(5):2525-34. doi: 10.1093/nar/gkv115. Epub 2015 Feb 17.
• [270] 1,25-Dihydroxyvitamin D3 suppresses gene expression of eukaryotic translation initiation factor 2 in human promyelocytic leukemia HL-60 cells. Cell Struct Funct. 2005;30(1):1-6. doi: 10.1247/csf.30.1.
• [271] Arsenic alters transcriptional responses to Pseudomonas aeruginosa infection and decreases antimicrobial defense of human airway epithelial cells. Toxicol Appl Pharmacol. 2017 Sep 15;331:154-163.
• [272] The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. Clin Cancer Res. 2016 May 15;22(10):2534-44. doi: 10.1158/1078-0432.CCR-15-1666. Epub 2016 Jan 5.
• [273] Application of the adverse outcome pathway concept for investigating developmental neurotoxicity potential of Chinese herbal medicines by using human neural progenitor cells in vitro. Cell Biol Toxicol. 2023 Feb;39(1):319-343. doi: 10.1007/s10565-022-09730-4. Epub 2022 Jun 15.
• [274] A novel long noncoding RNA AK001796 acts as an oncogene and is involved in cell growth inhibition by resveratrol in lung cancer. Toxicol Appl Pharmacol. 2015 Jun 1;285(2):79-88.
• [275] Comparison of transcriptome expression alterations by chronic exposure to low-dose bisphenol A in different subtypes of breast cancer cells. Toxicol Appl Pharmacol. 2019 Dec 15;385:114814. doi: 10.1016/j.taap.2019.114814. Epub 2019 Nov 9.
• [276] Quantitative proteomics and transcriptomics addressing the estrogen receptor subtype-mediated effects in T47D breast cancer cells exposed to the phytoestrogen genistein. Mol Cell Proteomics. 2011 Jan;10(1):M110.002170.
• [277] Benzo[a]pyrene-induced DNA damage associated with mutagenesis in primary human activated T lymphocytes. Biochem Pharmacol. 2017 Aug 1;137:113-124.
• [278] Persistence of epigenomic effects after recovery from repeated treatment with two nephrocarcinogens. Front Genet. 2018 Dec 3;9:558.
• [279] Adenosine and Cordycepin Accelerate Tissue Remodeling Process through Adenosine Receptor Mediated Wnt/-Catenin Pathway Stimulation by Regulating GSK3b Activity. Int J Mol Sci. 2021 May 25;22(11):5571. doi: 10.3390/ijms22115571.
• [280] Environmental pollutant induced cellular injury is reflected in exosomes from placental explants. Placenta. 2020 Jan 1;89:42-49. doi: 10.1016/j.placenta.2019.10.008. Epub 2019 Oct 17.
• [281] Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem. 2012 Dec 14;287(51):43137-55.
• [282] Growth inhibition of ovarian tumor-initiating cells by niclosamide. Mol Cancer Ther. 2012 Aug;11(8):1703-12.
• [283] Gene expression profile of colon cancer cell lines treated with SN-38. Chemotherapy. 2010;56(1):17-25. doi: 10.1159/000287353. Epub 2010 Feb 24.
• [284] Effects of paclitaxel on proliferation and apoptosis in human acute myeloid leukemia HL-60 cells. Acta Pharmacol Sin. 2004 Mar;25(3):378-84.
• [285] Analysis of nucleotide insertion opposite 2,2,4-triamino-5(2H)-oxazolone by eukaryotic B- and Y-family DNA polymerases. Chem Res Toxicol. 2015 Jun 15;28(6):1307-16. doi: 10.1021/acs.chemrestox.5b00114. Epub 2015 Jun 3.
• [286] Leukotriene biosynthesis inhibitor MK886 impedes DNA polymerase activity. Chem Res Toxicol. 2013 Feb 18;26(2):221-32. doi: 10.1021/tx300392m. Epub 2013 Jan 31.
• [287] Kynurenine Signaling Increases DNA Polymerase Kappa Expression and Promotes Genomic Instability in Glioblastoma Cells. Chem Res Toxicol. 2016 Jan 19;29(1):101-8. doi: 10.1021/acs.chemrestox.5b00452. Epub 2015 Dec 30.
• [288] Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profiling. Int J Cancer. 2004 Nov 1;112(2):200-12. doi: 10.1002/ijc.20401.
• [289] Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol Appl Pharmacol. 2009 Feb 1;234(3):345-60.
• [290] Prenatal arsenic exposure and shifts in the newborn proteome: interindividual differences in tumor necrosis factor (TNF)-responsive signaling. Toxicol Sci. 2014 Jun;139(2):328-37. doi: 10.1093/toxsci/kfu053. Epub 2014 Mar 27.
• [291] Clarifying off-target effects for torcetrapib using network pharmacology and reverse docking approach. BMC Syst Biol. 2012 Dec 10;6:152.
• [292] An approach to elucidate potential mechanism of renal toxicity of arsenic trioxide. Exp Hematol. 2007 Feb;35(2):252-62.
• [293] Neuronal and cardiac toxicity of pharmacological compounds identified through transcriptomic analysis of human pluripotent stem cell-derived embryoid bodies. Toxicol Appl Pharmacol. 2021 Dec 15;433:115792. doi: 10.1016/j.taap.2021.115792. Epub 2021 Nov 3.
• [294] Capsaicin inhibits the migration, invasion and EMT of renal cancer cells by inducing AMPK/mTOR-mediated autophagy. Chem Biol Interact. 2022 Oct 1;366:110043. doi: 10.1016/j.cbi.2022.110043. Epub 2022 Aug 28.
• [295] Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heat-shock proteins. Physiol Genomics. 2004 Jan 15;16(2):204-11.
• [296] Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun. 2018 Aug 9;9(1):3069. doi: 10.1038/s41467-018-05402-2.
• [297] Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
• [298] Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men. Clin Ther. 2011 May;33(5):655-63. doi: 10.1016/j.clinthera.2011.04.018.
• [299] Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46.
• [300] Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
• [301] Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005 Jun;77(6):468-78. doi: 10.1016/j.clpt.2005.01.018.
• [302] SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients. Toxicol Sci. 2014 Nov;142(1):196-209. doi: 10.1093/toxsci/kfu162. Epub 2014 Aug 14.
• [303] SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008 Aug 21;359(8):789-99.
• [304] Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res. 2006 Jun;47(6):1196-202.
• [305] Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
• [306] Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. Ther Drug Monit. 2007 Oct;29(5):666-8. doi: 10.1097/FTD.0b013e3181357364.